October 26, 2015.
Writing for the pharmaviews.eu blog on Friday, Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), called for a global “charter” to ensure that new antibiotics will be administered in a controlled manner and at affordable prices.
The new approach must "include de-linking revenues from selling, at least outside the richer countries in Europe and North America", wrote Bergström. "What I mean is that pharma companies should not have an incentive to sell as much as they can. Somehow they have to be rewarded differently, such as through an advanced purchase commitment (such as real or virtual stock-piling), or with transferable rights, reflecting the voucher system that is prevalent in the US."
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.